Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

被引：3

作者：

Kilickap, Saadettin ^{[1
]}

Guven, Deniz C. ^{[2
]}

Aktepe, Oktay H. ^{[2
]}

Aktas, Burak Y. ^{[2
]}

Dizdar, Omer ^{[1
]}

机构：

[1] Hacettepe Univ, Dept Prevent Oncol, Canc Inst, Ankara, Turkey

[2] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkey

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2020年 / 26卷 / 02期

关键词：

Complete response; melanoma; nivolumab; pembrolizumab; PEMBROLIZUMAB; APPROVAL; REINDUCTION; RESPONDERS; THERAPY;

D O I：

10.1177/1078155219858657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembrolizumab and also a complete response with nivolumab after progression during drug-free follow-up. We think that reinduction with a different anti-PD1 antibody may be used in patients with metastatic melanoma responders. Clinical trials with prespecified sequential treatment protocols and large real-life data can further delineate this subject.

引用

页码：496 / 499

页数：4

共 14 条

[1] The use of immunotherapy in the treatment of melanoma [J].

Achkar, Tala ;

Tarhini, Ahmad A. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10

[2] FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma [J].

Barone, Amy ;

Hazarika, Maitreyee ;

Theoret, Marc R. ;

Mishra-Kalyani, Pallavi ;

Chen, Huanyu ;

He, Kun ;

Sridhara, Rajeshwari ;

Subramaniam, Sriram ;

Pfuma, Elimika ;

Wang, Yaning ;

Li, Hongshan ;

Zhao, Hong ;

Zirkelbach, Jeanne Fourie ;

Keegan, Patricia ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5661-5665

[3] Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression [J].

Bernard-Tessier, A. ;

Baldini, C. ;

Martin, Patricia ;

Champiat, Stephane ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Varga, Andrea ;

Bahleda, Rastilav ;

Gazzah, Anas ;

Michot, Jean-Marie ;

Ribrag, Vincent ;

Armand, Jean-Pierre ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Massard, C. .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :160-164

[4] Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma [J].

Blasig, Hanna ;

Bender, Carolin ;

Hassel, Jessica C. ;

Eigentler, Thomas K. ;

Sachse, Michael M. ;

Hiernickel, Julia ;

Koop, Anika ;

Satzger, Imke ;

Gutzmer, Ralf .

MELANOMA RESEARCH, 2017, 27 (04) :321-325

[5]

Borcoman Edith, 2018, Am Soc Clin Oncol Educ Book, V38, P169, DOI 10.1200/EDBK_200643

[6] FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma [J].

Chuk, Meredith K. ;

Chang, Jennie T. ;

Theoret, Marc R. ;

Sampene, Emmanuel ;

He, Kun ;

Weis, Shawna L. ;

Helms, Whitney S. ;

Jin, Runyan ;

Li, Hongshan ;

Yu, Jingyu ;

Zhao, Hong ;

Zhao, Liang ;

Paciga, Mark ;

Schmiel, Deborah ;

Rawat, Rashmi ;

Keegan, Patricia ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5666-5670

[7] US FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab [J].

Hazarika, Maitreyee ;

Chuk, Meredith K. ;

Theoret, Marc R. ;

Mushti, Sirisha ;

He, Kun ;

Weis, Shawna L. ;

Putman, Alexander H. ;

Helms, Whitney S. ;

Cao, Xianhua ;

Li, Hongshan ;

Zhao, Hong ;

Zhao, Liang ;

Welch, Joel ;

Graham, Laurie ;

Libeg, Meredith ;

Sridhara, Rajeshwari ;

Keegan, Patricia ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2017, 23 (14) :3484-3488

[8] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [J].

Hodi, Frank Stephen ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Grob, Jean-Jacques ;

Rutkowski, Piotr ;

Cowey, Charles Lance ;

Lao, Christopher D. ;

Schadendorf, Dirk ;

Wagstaff, John ;

Dummer, Reinhard ;

Ferrucci, Pier Francesco ;

Smylie, Michael ;

Hill, Andrew ;

Hogg, David ;

Marquez-Rodas, Ivan ;

Jiang, Joel ;

Rizzo, Jasmine ;

Larkin, James ;

Wolchok, Jedd D. .

LANCET ONCOLOGY, 2018, 19 (11) :1480-1492

[9] The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma [J].

Ladwa, Rahul ;

Atkinson, Victoria .

MELANOMA RESEARCH, 2017, 27 (02) :168-170

[10] Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody [J].

Lipson, Evan J. ;

Sharfman, William H. ;

Drake, Charles G. ;

Wollner, Ira ;

Taube, Janis M. ;

Anders, Robert A. ;

Xu, Haiying ;

Yao, Sheng ;

Pons, Alice ;

Chen, Lieping ;

Pardoll, Drew M. ;

Brahmer, Julie R. ;

Topalian, Suzanne L. .

CLINICAL CANCER RESEARCH, 2013, 19 (02) :462-468

← 1 2 →